StockData
IRadimed Corp logo

IRadimed Corp (IRMD) company profile

IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3054% above fair value
$83.45−1.39 (-1.64%)

Close on Nov 17, 2026Market cap $1.07BP/E 44.6Yield –

About IRadimed

Surgical & Medical Instruments & Apparatus, SIC 3841

IRADIMED CORPORATION develops, manufactures, and sells medical devices, disposables, and services engineered for magnetic resonance imaging environments. Its core offerings include the MRidium 3870 and MRidium 3860+ non-magnetic intravenous infusion pump systems, proprietary single-use intravenous tubing sets, and the IRadimed 3880 patient vital signs monitoring system. The company also supplies ferromagnetic detection devices, replacement accessories, and maintenance contracts. Its products serve hospitals and acute care facilities worldwide, particularly radiology departments, intensive care units, emergency rooms, and surgical centers requiring continuous medication delivery and patient monitoring during scans.

The company distributes products in the United States and roughly 80 foreign countries. Within the United States, commercial operations rely on a direct sales force consisting of 29 field representatives, four regional sales directors, and ten clinical application specialists. Outside the domestic market, it markets products through third-party distributors. Cumulatively, the business has distributed roughly 13,098 infusion pump channels and 3,397 vital signs monitoring systems. The provided report does not state the location of the corporate headquarters.

Summary of the business section of IRadimed's latest annual report, written by StockData.

Company profile

Company

Legal name
IRadimed Corp
Founded
1992
Headquarters
Orlando, FL
Address
12705 Ingenuity Drive 32826
Phone
(407) 677-8022
Employees
166, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
RSM US LLP, Orlando, Florida

Stock & identifiers

Ticker
IRMD
Exchange
Nasdaq
IPO date
Jul 16, 2014
Shares outstanding
13M, Oct 30, 2026
Public float
$480.86M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1325618
CUSIP
46266A109
ISIN
US46266A1097
FIGI
BBG006NM92X2
Share class FIGI
BBG006NM92Y1
LEI
549300YVHWP0YJ1YW816
EIN
73-1408526

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Roger E. SusiCEO, President, Chairman, Director4,387,950
John GlennCFO14,256
Jeff ChiprinChief Commercial Officer996
Joe E. KianiDirector698
Monty K. AllenDirector19,986
Hilda Frederique Scharen-GuivelDirector5,598
James B. HawkinsDirector29,647
Anthony VuotoDirector17,181

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$780.60K$780.60K$569.68K$368–
FY2024$689.58K$689.58K$825.79K$205–
FY2023$642.57K$642.57K$932.30K$175–
FY2022$586.04K$586.04K$666.73K$63–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryIncentive payOtherTotalvs. prior year
Roger Susi
President and Chief Executive Officer
$385.60K$395.00K–$780.60K+13%
Jeffrey Chiprin
Chief Commercial Officer
$205.00K$228.00K$96.36K$529.36K+36%
John Glenn
Chief Financial Officer
$378.93K$200.00K$31.06K$609.99K-52%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 16, 2014
Offer price
$6.25
Securities offered
2,016,000
Gross proceeds
$12.60M
Exchange
Nasdaq
First trading day
Jul 16, 2014
First-day close
$9.90+58.4%
Lock-up ends (est.)
Jan 12, 2015

“The initial public offering price is $6.25 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 166 full-time employees, including 55 in manufacturing and service, 68 in sales, marketing and customer support services, 14 in regulatory affairs and quality assurance, 14 in finance and administration and 15 in research and development.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?